Overview
Roche acquired the Foundation Medicine shares it did not already own for $137 in cash per share, a $2.4bn transaction that put a $5.3bn fully diluted value on the cancer-genomics platform. The minority buyout completed a strategic relationship built through a 2015 majority investment, global commercialisation rights and joint R&D. The commercial question was control of the evidence layer connecting comprehensive genomic profiling, companion diagnostics and oncology drug development.
Roche turns a strategic holding into the data and diagnostics platform beneath precision oncology
Announced 19 June 2018. Completed through a tender offer and second-step merger in July 2018.
Roche bought the Foundation Medicine shares it did not already own for $137 in cash per share, a $2.4bn minority buyout that put a $5.3bn fully diluted value on the cancer-genomics company. The commercial significance was larger than the legal step: Roche moved from majority owner and distribution partner to sole owner of a platform connecting genomic profiling, companion diagnostics, oncology drug development and clinical decision support. [[1]](https://www.roche.com/media/releases/med-cor-2018-06-19)
The deal followed three years in which Roche had used a majority stake, an R&D collaboration and ex-US commercial rights to build the relationship. At signing, Roche controlled approximately 56.6% of Foundation Medicine’s outstanding shares. The remaining purchase consolidated an asset already woven into Roche’s personalised-healthcare strategy. [[2]](https://www.sec.gov/Archives/edgar/data/1488613/000119312518210360/d614177dsc14d9.htm)
“Molecular insights and the broad availability of high quality comprehensive genomic profiling are key enablers for the development of, and access to, new cancer treatments.” Daniel O’Day, Roche Pharmaceuticals CEO, 19 June 2018
Roche paid up for control of a high-growth but loss-making diagnostics and data platform at the point where FDA approval, Medicare coverage and global distribution were beginning to make comprehensive genomic profiling commercially scalable.
A cash tender offer converted a controlled public company into a wholly owned affiliate
The consideration and legal path were explicitly disclosed. The underlying merger agreement and 14D-9 provide the operative record.
| Term | Detail | Source status |
|---|---|---|
| Acquirer | Roche Holdings, Inc., through 062018 Merger Subsidiary, Inc. | Public record |
| Target | Foundation Medicine, Inc., then NASDAQ: FMI | Public record |
| Announcement | 19 June 2018 | Public record |
| Consideration | $137.00 cash per share for shares outside Roche’s ownership | Public record |
| Transaction value | $2.4bn, fully diluted, for the remaining shares | Public record |
| Total company value | $5.3bn, fully diluted | Public record |
| Premium | 29% to 18 June 2018 close; 47% and 68% to 30-day and 90-day VWAP | Public record |
| Closing mechanism | Tender offer followed by a Section 251(h) second-step merger | Public record |
| Advisers | Citi and Davis Polk for Roche; Goldman Sachs and Goodwin Procter for Foundation Medicine’s special committee | Public record |
Roche disclosed all core economic terms. Financing sources, break-fee terms and retention arrangements were not itemised in the announcement materials reviewed for this page. That is the only disclosure gap relevant to the headline transaction structure.
A molecular-information business with clinical, biopharma and data feedback loops
Foundation Medicine offered a comprehensive genomic profiling platform rather than a single diagnostic product.
Foundation Medicine’s clinical assays profiled tumour tissue and blood to identify genomic alterations, match patients with relevant targeted therapies and immunotherapies, and surface clinical-trial options. Its business combined physician-ordered testing with work for biopharma customers, including clinical-study testing, biomarker work and companion diagnostic development. [[3]](https://www.sec.gov/Archives/edgar/data/1488613/000156459018004758/fmi-10k_20171231.htm)
FoundationOne CDx
The FDA approved the broad companion diagnostic assay for solid tumours in November 2017. CMS followed with nationwide Medicare coverage in March 2018 for eligible advanced-cancer patients.
Data that informs development
Pharma customers used the platform for profiling, trial design, biomarker discovery and companion diagnostic programmes, creating a customer base alongside clinical testing.
FoundationCORE
Each profiled tumour added to an evolving molecular information base. The strategic value sat in the loop between testing volume, evidence generation and oncology R&D.
Roche’s current profile says Foundation Medicine remains an independent affiliate with more than 1,700 employees and CGP tests analysing more than 300 cancer-related genes. That scale is a later outcome, not a 2018 deal metric, but it illustrates the platform Roche chose to consolidate. [[4]](https://www.roche.com/innovation/structure/foundation-medicine)
The price captured strategic momentum while the operating model was still being built out
The key valuation tension was straightforward: rapid revenue growth and a widening data moat against meaningful operating losses and capital needs.
Foundation Medicine reported $152.9m of 2017 revenue, up 31% year on year, and $57.0m for the second quarter of 2018, up 63% year on year. Annualising the second-quarter run rate produces $228.0m, which puts the $5.3bn company value at 23.2× annualised Q2 revenue. Using 2017 reported revenue, the same figure is 34.7×. Both are Acquiry calculations and are revenue reference points, not EBITDA multiples. [[5]](https://www.foundationmedicine.com/press-releases/foundation-medicine-announces-2017-fourth-quarter-and-year-end-results%2C-recent-highlights-and-2018-outlook) [[6]](https://www.sec.gov/Archives/edgar/data/1488613/000156459018021082/fmi-10q_20180630.htm)
The company was still consuming cash. In the first half of 2018 it reported a $70.8m net loss and $60.2m of net cash used in operating activities. Roche funding was already part of the capital structure, with $110m of non-current indebtedness to Roche at 30 June 2018. The buyout therefore secured an operating asset and removed the public-market funding question at the same time. [[6]](https://www.sec.gov/Archives/edgar/data/1488613/000156459018021082/fmi-10q_20180630.htm)
Acquiry calculation$5.3bn total company value ÷ $228.0m annualised Q2 2018 revenue = 23.2×Annualised revenue is a reference framework, not company guidance.
Roche paid for control where diagnostics, drug development and global access meet
The 2015 alliance had already outlined the logic. The 2018 buyout brought control, duration and capital allocation inside the group.
FoundationOne CDx had a recently established regulatory and reimbursement foothold. Ownership aligned the diagnostic platform with Roche’s oncology portfolio and companion-diagnostic agenda.
Roche already held ex-US commercialisation rights for several tests. Full ownership gave it a single decision path for global launch, investment and product evolution.
CGP testing, biopharma research and companion diagnostics compounded the value of a common molecular information base. Control reduces coordination cost across those activities.
Foundation Medicine’s revenue momentum came with substantial research, laboratory and commercial spend. A private affiliate structure matched that investment profile.
A global commercial network was already built into the relationship
In 2015, Roche and Foundation Medicine paired a majority investment with an ex-US commercialisation agreement. Roche’s distribution platform was part of the design from the outset, alongside joint R&D, medical education and companion-diagnostic work.
The operating evidence Roche was buying
All figures are historical disclosures from the last full year and first half before completion.
Revenue split mattered. In 2017, Foundation Medicine reported $99.7m from biopharmaceutical customers and $53.2m from clinical testing. The blended model meant a Roche oncology pipeline could benefit from the target’s data and trial capabilities while a growing clinical base expanded the evidence set. [[5]](https://www.foundationmedicine.com/press-releases/foundation-medicine-announces-2017-fourth-quarter-and-year-end-results%2C-recent-highlights-and-2018-outlook)
The relevant precedent was Roche’s own staged acquisition
This was the final leg of a strategic relationship, rather than a fresh auction for an unencumbered target.
Roche’s 2015 transaction combined an approximately $780m tender offer with a $250m primary investment at $50 per share. It left Roche with between 52.4% and 56.3% on a fully diluted basis and paired the ownership stake with R&D and commercial agreements. By June 2018, the $137 offer price was 2.74× the 2015 price per share. [[7]](https://www.foundationmedicine.com/press-releases/foundation-medicine-enters-a-broad%2C-strategic-collaboration-with-roche-in-the-field-of-molecular-information-in-oncology)
Revenue reference points frame the price more usefully than generic diagnostics comparables
The asset combined laboratory testing, regulated diagnostics, biopharma services and molecular data. Comparable-company screens capture only part of that mix.
Foundation Medicine’s $5.3bn value was 34.7× 2017 revenue and 23.2× annualised second-quarter 2018 revenue. The remaining-share consideration was 15.7× 2017 revenue. The spread is a reminder that the $2.4bn figure relates to the minority interest, while the $5.3bn figure is the appropriate starting point for total-company valuation. [[6]](https://www.sec.gov/Archives/edgar/data/1488613/000156459018021082/fmi-10q_20180630.htm)
From a $50 strategic entry price to $137 for full control
The change reflects more than a public-market re-rating. In the intervening period, the partnership established a broad collaboration, Roche became the global distribution partner for key products, and FoundationOne CDx gained FDA approval and Medicare coverage.
Four figures describe four different economic views of the same company
| Figure | What it measures | How to use it |
|---|---|---|
| $50 per share | 2015 Roche tender and primary investment price | Strategic entry point |
| $1.03bn | 2015 tender plus primary investment | Capital invested to gain majority control |
| $2.4bn | 2018 remaining-share consideration | Cash cost to complete ownership |
| $5.3bn | 2018 fully diluted total company value | Total-company valuation reference |
Conflating the $2.4bn buyout cost with the $5.3bn company value would flatten an important ownership distinction. Roche already owned a majority stake before the tender, so it paid for the minority while valuing the whole enterprise.
Roche’s capital relationship progressed from investor to lender to sole owner
The financing history is also the integration history.
Roche affiliate bought Series B preferred shares, later converted into common stock.
Roche acquired 15.6m shares for about $780.2m and invested $250m in new shares.
Foundation Medicine drew on a Roche Finance credit facility, reporting $110m non-current indebtedness at 30 June 2018.
Roche completed the tender and merger, taking Foundation Medicine private.
The capital stack placed Roche across every layer of the relationship: shareholder, commercial collaborator, creditor and eventual owner. That structure made an arm’s-length auction an unlikely organising principle for the final transaction. Acquiry inference
Independent operating company, Roche-controlled strategic platform
Both the 2015 collaboration and the 2018 announcement emphasised Foundation Medicine’s continuing autonomy. The governance choice preserved the specialist brand and external biopharma relationships while Roche absorbed the ownership and funding risk.
The $2.4bn was consideration for the minority; the $5.3bn was the value of the whole
At announcement, Roche owned roughly 56.6% of Foundation Medicine’s outstanding shares. The $2.4bn transaction value represented the disclosed consideration for the shares outside that position. The difference between $5.3bn total company value and $2.4bn consideration is $2.9bn, which is a valuation context for Roche’s pre-existing interest, not a new cash payment. Acquiry calculation
Regulatory validation and reimbursement support shifted the commercial horizon
FoundationOne CDx was approved by the FDA in November 2017 as a broad companion diagnostic for solid tumours. CMS issued a final National Coverage Determination in March 2018 establishing nationwide Medicare coverage for eligible advanced-cancer patients. Those events supplied clinical and payment infrastructure at a point when biopharma demand for biomarker-led development was expanding. [[6]](https://www.sec.gov/Archives/edgar/data/1488613/000156459018021082/fmi-10q_20180630.htm)
For Roche, the commercial question was less about buying a test catalogue than controlling an operating system for oncology evidence. Profiling volume could contribute to patient care, clinical trial enrolment, drug development and companion diagnostics. That combination explains why revenue multiples alone leave much of the deal logic unexplained. Acquiry inference
The advantage lay in proof, distribution and the ability to compound a data set
Clinical validation
FDA approval and CMS coverage for FoundationOne CDx created a regulated route into routine oncology practice.
Biopharma relevance
Pharma services brought external data demand, trial activity and companion-diagnostic opportunities into the platform.
Global distribution
Roche’s ex-US commercial rights and oncology presence gave the asset a pathway that an independent specialist would have needed years to build.
Competition remained real across liquid biopsy, tissue sequencing, laboratory services and broader oncology data. The core strategic distinction was Roche’s ability to join diagnostics, therapeutics and market access within one group while maintaining Foundation Medicine as a specialist operating entity. Acquiry inference
Five routes from ownership to commercial value
Use the FoundationOne CDx regulatory and coverage base to expand testing adoption across geographies and tumour settings.
Bring molecular profiling, biomarker work and companion-diagnostic development closer to the drug portfolio.
Use global scale and a growing molecular-information base to deepen work with external drug developers.
Higher test throughput and a wider commercial network can spread fixed laboratory, regulatory and sales costs.
Retain ownership of the testing-to-evidence loop as precision oncology becomes more biomarker-led.
Execution depends on clinical adoption, reimbursement and data stewardship
Reimbursement expansion
Coverage breadth and payment levels influence clinical uptake and the economics of each test.
Competitive technology change
Liquid biopsy, lower-cost sequencing and alternative testing approaches could change the product mix.
Laboratory scale
Volume growth requires reliable operations, quality control and continued capital investment.
External-partner trust
Biopharma customers may require confidence that the autonomous operating model protects collaboration choice.
Regulatory evolution
Diagnostics regulation and companion-diagnostic requirements can add cost and alter commercial timing.
Data governance
Molecular information has high strategic value and requires careful security, privacy and access controls.
These are operating execution questions, rather than challenges to the transaction rationale. Roche’s control and capital capacity address some of them; clinical adoption and reimbursement remain market-dependent.
Full ownership brought Foundation Medicine’s investment needs inside Roche
At 30 June 2018, Foundation Medicine reported $53.4m of cash, $110m of non-current indebtedness to Roche and $60.2m of first-half operating cash use. Taking the company private reduced dependence on the public equity market as it funded laboratory, regulatory, R&D and commercial growth.
Roche bought control while retaining the specialist operating model
The announcement said Foundation Medicine would continue as a separate and autonomous legal entity. That was commercially sensible: the asset’s value depended on its role across multiple biopharma customers and on a specialist brand within precision oncology. Roche’s current corporate profile continues to describe Foundation Medicine as an independent affiliate. [[1]](https://www.roche.com/media/releases/med-cor-2018-06-19) [[4]](https://www.roche.com/innovation/structure/foundation-medicine)
Acquiry inference: the deal’s integration thesis was coordination without absorption. Roche could centralise capital allocation, global access and portfolio linkage while leaving the laboratory, clinical and external-partner front end close to the domain expertise that made the target valuable.
A six-year progression from minority investor to sole owner
Roche affiliate invests in Foundation Medicine’s Series B.
Roche announces majority investment, R&D collaboration and commercial agreements.
2015 investment closes, giving Roche a majority position.
FDA approves FoundationOne CDx.
CMS establishes nationwide coverage for eligible FoundationOne CDx patients.
Roche announces $137-per-share cash offer for remaining shares.
Roche accepts tendered shares and moves to complete the merger.
A clearer capital and distribution path for the platform, with a changed ownership backdrop for partners
Roche
Gained full control over a precision-oncology platform already connected to its drug-development and diagnostics activities.
Foundation Medicine
Gained access to Roche’s capital base and global operating reach while preserving an autonomous affiliate structure.
Minority holders
Received a cash exit at $137 per share, a 29% premium to the preceding close.
Biopharma partners
Inherited a more deeply Roche-owned collaborator, alongside an explicit commitment to operate independently.
Roche’s two-engine model made the target strategically legible
Roche combined pharmaceuticals and diagnostics under one group and had made personalised healthcare a stated strategic priority. Foundation Medicine strengthened the molecular information layer linking those engines in oncology.
A strategically coherent consolidation that valued a future platform, not current profit
Roche’s price recognised a company moving from specialist testing provider toward a broader precision-oncology infrastructure role. The multiple was high against reported revenue and the target was loss-making, yet the deal joined assets that had already been operationally linked for three years: molecular profiling, companion diagnostics, oncology R&D, global commercialisation and a growing clinical data set.
Acquiry inference: Roche’s core wager was that ownership of the molecular information layer would improve both the economics and the strategic reach of its oncology franchise over a longer horizon than public-market investors were prepared to finance. The current scale of the independent affiliate offers evidence that the operating model remained central to that thesis, although it cannot isolate the economic contribution of the 2018 deal.
The durable questions sit in coverage, data scale and partner confidence
How far reimbursed CGP testing moves beyond the initial Medicare foundation.
Whether growing clinical use compounds the molecular-information base and product evidence.
The extent to which external drug developers continue to use the platform alongside Roche programmes.
How Roche’s global network translates approved products into local launch and reimbursement.
Whether the independent-affiliate model continues to support customer trust and specialist execution.
Data labels and method
Public record identifies company releases, SEC filings and current corporate pages. Acquiry calculation identifies arithmetic based on disclosed figures. Acquiry inference identifies clearly labelled interpretation of the transaction’s strategic logic.
Revenue-reference calculations use the total company value where comparing the whole asset, and use the remaining-share consideration only where discussing the cash cost of completing ownership. Interim revenue is annualised solely to provide a transparent reference frame.
Frequently asked questions
What did Roche pay for Foundation Medicine?
Roche paid $137.00 in cash per share for shares it and its affiliates did not already own. The disclosed fully diluted transaction value was $2.4bn and the stated fully diluted total company value was $5.3bn.
Why are there both $2.4bn and $5.3bn figures?
$2.4bn was the value of the remaining-share purchase. $5.3bn was the company’s stated fully diluted total value. Roche already held approximately 56.6% before the tender.
Was the transaction cash or stock?
The offer was $137.00 per share in cash. Roche’s tender-offer materials stated that the offer was free of a financing condition.
When did the transaction complete?
Roche accepted tendered shares for payment on 31 July 2018 and then completed the acquisition through a second-step merger.
What was the strategic rationale?
Roche connected a majority-owned molecular profiling platform more tightly to its oncology, diagnostics, companion-diagnostic and global commercialisation activities.
What was Foundation Medicine’s revenue before completion?
The company reported $152.9m in FY2017 revenue and $57.0m in Q2 2018 revenue. Those figures are historic company disclosures.
What revenue multiple did the deal imply?
Acquiry calculates 34.7× FY2017 revenue and 23.2× annualised Q2 2018 revenue using the $5.3bn total company value. These are revenue reference points, not EBITDA multiples.
Why did Roche pay a high revenue reference point?
The price reflected a platform with regulatory validation, Medicare coverage, growing test volume, a biopharma services business and a data set relevant to precision-oncology development.
Who advised the parties?
Citi and Davis Polk advised Roche. Goldman Sachs and Goodwin Procter advised Foundation Medicine’s special committee.
Did Foundation Medicine retain autonomy?
Yes. The announcement said it would operate as a separate and autonomous legal entity; Roche’s current profile describes it as an independent affiliate.
What was Roche’s ownership before the offer?
The Schedule 14D-9 reported 21,019,111 shares, approximately 56.6% of shares outstanding, held by Roche and affiliates as of 25 June 2018.
What does the 2015 investment add to the analysis?
It shows the full acquisition was the culmination of a staged strategic relationship involving equity, R&D, distribution and later credit funding.
What are the key execution questions?
Reimbursement, clinical adoption, data stewardship, laboratory scale, technology competition and the confidence of external biopharma partners remain the operating questions.
How should the deal be read today?
As a historical strategic consolidation in precision oncology. Current operating scale is relevant as context but does not attribute financial outcomes to the 2018 transaction.
Sources
- 1
- 2
- 3
- 4
- 5
- 6
- 7
Joash Boyton is a technology sector analyst, publisher, and the founder of Acquiry, where he executes buy-side and sell-side M&A mandates across digital assets, software, and gaming technologies. He is the author of peer-reviewed corporate finance literature indexed across institutional repositories including Google Scholar and the ORCID Registry. Joash publishes Acquiry Deal Intelligence to deliver independent, forensic strategic reviews and valuation benchmarks of global technology acquisitions, compiling primary data directly from corporate disclosures, SEC filings, and regulatory ledgers.
Research support: Acquiry Deal Intelligence.